Table 1.
Long-term survivors following treatment for recurrent small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
| Study author, year | FIGO stage | Age at diagnosis (years) | Primary surgery | Primary adjuvant treatment | Recurrence interval (months) | Recurrence site | Treatment for recurrence | Outcome |
|---|---|---|---|---|---|---|---|---|
|
Cannon et al. (1975), Young et al. (1994) |
IA | 23 | RSO | None | 12 | Pelvis | Surgery: resection of the right broad ligament. Radiotherapy: pelvis Chemotherapy: chlorambucil |
NED at 10 years |
| Dickersin et al. (1982) | IA | 26 | RSO | Radiotherapy | 2 | Para-aortic LN and omentum | Surgery: TH, LSO and retroperitoneal LN dissection | NED at 9 months |
| Young et al. (1994) | IA | 19 | RSO | Chemotherapy: cisplatin, velban, bleomycin | 4 18 |
Pelvis Anterior abdominal wall |
Surgery: TH and LSO Chemotherapy: doxorubicin, cyclophosphamide, etoposide Radiotherapy: pelvis Surgery: resection of mass Chemotherapy: doxorubicin, cyclophosphamide, etoposide |
NED at 45 months |
| Young et al. (1994) | IA | 10 | LSO | Chemotherapy: cisplatin, velban | 5 | Para-aortic LN | Chemotherapy: cisplatin, velban, doxorubicin, vinblastine, etoposide | NED at 4 years, 5 months |
| (Young et al. (1994), Benrubi et al. (1993)) | IIB | 16 | RSO | Chemotherapy: cyclophosphamide, doxorubicin, cisplatin, vincristine, etoposide Surgery: TH, LSO, omentectomy, appendectomy, para-aortic and pelvic LN dissection |
6 | NR | Surgery: TH, LSO, omentectomy, para-aortic LN dissection. Radiotherapy: whole abdomen |
NED at 7 years |
| Harrison et al. (2006) | IC | 28 | USO, omentectomy | Chemotherapy: cisplatin, etoposide and carboplatin, paclitaxel | 9 | NR | Surgery: USO and omentectomy. | NED at 16 months |
| Niimi et al. (2006), Isonishi et al. (2008) | IIC | 24 | LSO, omentectomy | Chemotherapy: cisplatin, etoposide, docetaxel | 8 | Uterus | Surgery: TH and pelvic lymphadenectomy. Chemotherapy: docetaxel | NED at 4 years |
| Christin et al. (2008) | IIIC | 12 | LSO and para-aortic LN dissection | Chemotherapy: doxorubicin, etoposide, cisplatin, cyclophosphamide, carboplatin Surgery: RSO, omentectomy, pelvic and para-aortic LN dissection |
2 | Pelvis | Surgery: resection of parietal nodule and TH. Chemotherapy: carboplatin and ifosfamide followed by high-dose chemotherapy (carboplatin, etoposide, melphalan) with autologous bone marrow transplantation | NED at > 14 years |
| Christin et al. (2008) | IIC | 13 | LSO and omentectomy | Chemotherapy: bleomycin, etoposide, cisplatin, ifosfamide Surgery: TAH, RSO, omentectomy, pelvic and para-aortic LN dissection |
0 | Para-aortic LN | Chemotherapy: ifosfamide and etoposide, followed by high-dose chemotherapy (carboplatin, etoposide, melphalan) with autologous bone marrow transplantation. | NED at > 10 years. |
| Callegaro-Filho (2014) | IA | 35 | TH, BSO, and omentectomy | Chemotherapy: cisplatin, etoposide | 20 | Para-aortic LN | Surgery: para-aortic LN dissection and biopsy of the omentum. Radiotherapy: para-aortic LN |
NED at 15 years |
TH: total hysterectomy; BSO: bilateral salpingo-oophorectomy; LSO: left salpingo-oophorectomy; RSO: right salpingo-oophorectomy; LN: Lymph node; NED: no evidence of disease.